Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of TAK-226 for Anemia in Japanese Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT07319845 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07319845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07319845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of TAK-226 for Anemia in Japanese Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Recruiting
Start date
April 22, 2026
Completion date
January 10, 2033
Enrollment
42 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes